Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Firdapse
Pharma
Catalyst's Teva settlement postpones arrival of Firdapse generic
Thanks to a new settlement with Catalyst, Teva is barred from marketing its Firdapse generic in the U.S. until Feb. 25, 2035, at the earliest.
Fraiser Kansteiner
Jan 9, 2025 10:08am
Eisai peddles US rights to epilepsy drug Fycompa to Catalyst
Dec 20, 2022 10:35am
Catalyst one-ups Jacobus, FDA in Firdapse exclusivity appeal
Oct 1, 2021 12:11pm
Catalyst sues FDA over 'capricious' approval for rival
Jun 12, 2019 10:45am
Catalyst's $375K Firdapse could get off-label competition
May 7, 2019 12:02pm
Patient group urges BIO to boot Catalyst over $375K Firdapse price
Mar 7, 2019 10:20am
